Exchange Traded Concepts LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 485.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,899 shares of the medical equipment provider's stock after acquiring an additional 6,549 shares during the quarter. Exchange Traded Concepts LLC's holdings in Lantheus were worth $771,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in LNTH. Kestra Investment Management LLC acquired a new position in shares of Lantheus in the fourth quarter worth about $27,000. Summit Securities Group LLC purchased a new position in shares of Lantheus in the 4th quarter valued at about $37,000. Parkside Financial Bank & Trust raised its holdings in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares during the period. UMB Bank n.a. boosted its position in Lantheus by 68.2% during the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after purchasing an additional 381 shares in the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in Lantheus in the fourth quarter valued at approximately $125,000. Hedge funds and other institutional investors own 99.06% of the company's stock.
Lantheus Trading Up 0.2%
NASDAQ:LNTH traded up $0.14 during trading hours on Tuesday, hitting $80.95. The company had a trading volume of 943,124 shares, compared to its average volume of 1,014,644. Lantheus Holdings, Inc. has a 1 year low of $73.11 and a 1 year high of $126.89. The company has a market cap of $5.60 billion, a P/E ratio of 23.00 and a beta of 0.11. The company has a 50-day moving average of $86.36 and a 200 day moving average of $90.97. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49.
Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period in the previous year, the firm posted $1.69 EPS. The company's revenue was up .8% compared to the same quarter last year. Sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on LNTH. B. Riley decreased their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $130.50.
Read Our Latest Analysis on Lantheus
Insider Activity
In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director now owns 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.00% of the company's stock.
Lantheus Company Profile
(
Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Featured Articles

Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.